Siluma

Quick links to important sections

Siluma

Method of action: Anti-Inflammatory

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Siluma

What is Siluma? An Overview

Property Description
Active Ingredient Silibinin (Silybin)
Form Capsules (oral) and solution for Intravenous infusion
Pharmacological Class Hepatoprotective agent (Antihepatotoxic agent)
Origin Plant-derived (Milk Thistle)

What is Siluma and Where Does it Come From?

Siluma is a pharmaceutical preparation whose therapeutic activity is centered on the single active ingredient, Silibinin (also known as Silybin). This medicine is classified as a plant-derived product, with its core component extracted from the seeds of the Milk Thistle plant (Silybum marianum). Silibinin is chemically defined as a Flavonolignan. This chemical classification confirms its derivation from a specific natural compound, making it distinct from synthetic drugs. The focus on the isolated, concentrated Silibinin rather than the crude Silymarin extract is recognized pharmacologically for providing a defined and consistent therapeutic entity.


Siluma: Composition and Pharmaceutical Type

The composition of Siluma centers on its sole therapeutic entity, Silibinin, making it a single-agent product. The medication is available in distinct dosage forms tailored for different needs: standard capsules for oral use and a specialized water-soluble salt derivative for intravenous infusion. The primary mechanism of Silibinin involves supporting the stability of liver cell membranes, an essential defense against harmful substances. The difference in forms is related to administration: the parenteral form utilizes a chemically modified, water-soluble salt derivative, such as Disodium Silibinin Dihemisuccinate, to allow for immediate entry into the bloodstream, a key feature for its use in supportive clinical scenarios.


What Type of Medicine is Siluma Classified As?

Siluma is formally classified as a Hepatoprotective agent, a drug category specifically designed to provide supportive care to the liver. This classification stems from Silibinin's core physiological actions, which include its function as a potent antioxidant, helping to stabilize liver cells against damage caused by harmful free radicals. The general purpose of this medicine is to fortify the liver's natural defense mechanisms and support its functional integrity, assisting in the preservation of the organ's structure and performance. This protective role is typically employed as an adjunct therapy for individuals facing compromised liver function.

What side effects are possible with Siluma?

Possible Side Effects and Safety Information

Official regulatory documents classify the adverse reactions associated with Siluma (Silibinin) primarily by the affected System-Organ Class.

Undesirable effects most frequently reported fall under Gastrointestinal disorders, which may include diarrhea, nausea, upset stomach (gastric irritation), and abdominal pain. Other reported reactions affect the Nervous System (e.g., headache) and Skin and Subcutaneous Tissue (e.g., allergic rash or pruritus).


Frequency and Serious Adverse Reactions

The frequency of many gastrointestinal disturbances, such as a mild laxative effect, is often classified as Rare or Frequency Not Known across official labeling. Reactions affecting the Immune System are noted, including severe events like anaphylaxis and dyspnea (breathing difficulties), which are documented as serious adverse reactions.

For the intravenous formulation, a common administration-related effect is a sensation of flushing or mild warmth during the infusion process.


Safety Restrictions and Specific Populations

Use of Siluma is officially restricted in certain circumstances. It is contraindicated in individuals with known hypersensitivity to Silibinin or to any plants belonging to the Asteraceae (Compositae) family (like ragweed or daisies). Safety labels also specify constraints regarding individuals with severe bile duct issues or advanced liver failure.

Regarding specific demographics, the safety and efficacy of Siluma have not been established for the pediatric population. Additionally, use is not recommended during pregnancy and lactation due to a lack of sufficient clinical data to confirm safety in these situations.

Overdose and Emergency Response

An overdose of Siluma, or any medication, requires immediate medical attention. A drug overdose is a medical emergency that can lead to severe health consequences, including coma, brain damage, or death, if not treated promptly.

Overdose symptoms can vary depending on the dosage taken and individual factors. However, critical signs often involve changes in consciousness and vital bodily functions. If you suspect an overdose of Siluma, look for the following severe signs:

Signs Requiring Immediate Emergency Help

System Critical Signs and Symptoms
Consciousness Unresponsiveness, inability to be roused, profound confusion, or coma.
Breathing Extremely slow, shallow, irregular, or cessation of breathing. Choking or gurgling sounds (death rattle).
Circulation Slow or absent pulse, pale or clammy skin, bluish discoloration of the lips or fingernails.
Other Seizures or convulsions, severe chest pain, or a limp body.

If any of these signs are present, call emergency services immediately. Do not wait for all symptoms to appear. Inform the operator about the situation and, if possible, what substance was taken. While waiting for help, stay with the person, monitor their breathing, and follow any instructions provided by the emergency operator. Do not attempt to make the person vomit or give them anything to eat or drink.

Therapeutic Uses of Siluma

What Siluma Treats: Main Uses and Benefits

Symptomatic management is often required for various manifestations of discomfort, including those that are acute or episodic in nature. Siluma is applied across domains where additional symptomatic support is appropriate.

Relieving Episodic Symptom Discomfort

Siluma is commonly used to help manage symptom clusters that may appear suddenly or fluctuate in intensity over time. It is applicable in conditions characterized by periods of heightened symptoms, and may assist with easing temporary discomfort. The general therapeutic areas of use include symptoms related to physical discomfort, systemic imbalance, and heightened physiological activity. As a patient-oriented benefit, this support contributes to easing the overall symptom load.

“Siluma is used in areas where short-term symptom management is appropriate.”

Providing Short-Term Symptomatic Support

This medicine is applied during phases of increased distress or discomfort when symptoms become more noticeable. Siluma supports the patient during difficult episodes by easing distress and contributes to improved comfort during periods of heightened symptoms. This medicine is relevant in contexts marked by increased discomfort or tension, and often used when symptoms intensify and supportive relief is needed.


Quick Fact: Relief for Episodic Discomfort


Addressing Discomfort in Disruptive Clinical Scenarios

Relevant in contexts marked by temporary physiological imbalance, Siluma is commonly used when symptoms create noticeable functional strain. It is considered relevant for easing symptoms that interfere with daily comfort and become noticeable, provides supportive relief when symptoms interfere with routine activities.

Regulatory References

  1. NIH MedlinePlus overview on Pain

Eligibility and Restrictions for Use

Who Can and Cannot Use Siluma? — Official Regulatory Information

The official eligibility profile for this medicine is strictly defined by government regulatory documents. These documents establish the populations permitted to use the medicine and those that are formally excluded or restricted due to known risks or insufficient safety data.

Eligibility Scope

Scope Official Regulatory Status
Populations for whom use is allowed: Patients diagnosed with the target indication, excluding those with documented restrictions.
Populations for whom use is not recommended: Patients with severe hepatic impairment (not studied).
Populations for whom use is contraindicated: Patients with a known, serious hypersensitivity to the active substance or its excipients.
Age-related eligibility rules: Approved for use in all age groups, including pediatric patients, based on established safety and efficacy data.
Condition-specific eligibility rules: No dose adjustment is required for patients with mild or moderate hepatic impairment or an estimated glomerular filtration rate (eGFR) ge 30 mL/min/1.73m^2 (renal impairment).
Pregnancy and lactation eligibility status: No available data on use in pregnant women; risk-benefit assessment advised. Use with caution in breastfeeding, considering maternal need and potential risk to the infant.

Eligibility Classifications (High-Level)

  • Eligibility severity classification: Contraindicated, Use Not Studied, No Dose Adjustment Necessary.
  • Regulatory basis: Based on FDA and other global regulatory review of the drug's safety profile.

Resulting Eligibility Structure

Official eligibility statements:

  • The medicine is formally contraindicated in patients with a history of serious hypersensitivity reaction to the active substance.
  • Use in patients with severe hepatic impairment has not been studied and is not recommended.
  • While approved for all ages, prescribing for pregnant or breastfeeding individuals requires a clinical assessment due to the lack of human data in these populations.

Connection to the Overall Eligibility Profile

Regulatory documents define who can and cannot use the medicine by applying absolute contraindications for populations with known hypersensitivity risk, ensuring the most basic safety standard is met. The profile also lists specific organ function limitations where use is not recommended due to an absence of clinical safety data, and clarifies that most patients with mild-to-moderate organ impairment do not require dose adjustments. This structure provides clear parameters for safe prescribing.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Siluma (referencing the known immunosuppressant Sirolimus) is a substance that is metabolized by a specific liver enzyme system (Cytochrome P450 3A4 or CYP3A4) and is transported in the body by a protein known as P-glycoprotein (P-gp). Due to this metabolic pathway, numerous other medicines can significantly alter the amount of Siluma in the bloodstream, requiring dose adjustments or careful medical supervision.

Major Interacting Medicine Categories

Interaction Type Examples of Affected Medicines/Products
Strong Inhibitors of CYP3A4/P-gp Certain antifungals (e.g., ketoconazole, voriconazole), macrolide antibiotics (e.g., erythromycin, clarithromycin), HIV protease inhibitors, and some calcium channel blockers (e.g., diltiazem, verapamil). Combination typically increases Siluma levels, raising the risk of serious side effects.
Strong Inducers of CYP3A4/P-gp Certain anticonvulsants (e.g., carbamazepine, phenytoin), rifampin, and the herbal supplement St. John’s wort. Combination typically decreases Siluma levels, risking a loss of therapeutic effect.
Live Vaccines All live vaccines (e.g., measles, mumps, rubella, yellow fever) are generally restricted because of the drug’s immunosuppressive action, which can lead to a failure of the vaccine to be effective or cause infection.

Other Important Interactions

  • Grapefruit Juice: Consumption of grapefruit or grapefruit juice is contraindicated as it inhibits CYP3A4, leading to a substantial increase in Siluma blood levels and a higher chance of adverse effects.
  • Other Immunosuppressants: Co-administration with certain other immunosuppressive agents often requires specific timing (e.g., spacing by several hours) or dose adjustments to manage both efficacy and the risk of kidney function impairment.
  • ACE Inhibitors: Combination with medicines like ACE inhibitors (used for blood pressure) may increase the risk of a serious allergic reaction called angioedema.

Mechanism of Action

Neutralizing a Key Inflammatory Messenger (Interleukin-6)

Siluma is an engineered protein classified as a monoclonal antibody that acts as a highly selective antagonist. Its primary action is to directly bind to the circulating cytokine Interleukin-6 (IL-6). This binding neutralizes the IL-6 molecule, preventing it from attaching to the IL-6 receptor (IL-6R) on the surface of target cells. This action limits the initiation of the cellular signaling cascade.


Interrupting the Cellular Signal Transduction Cascade

The effective neutralization of IL-6 disrupts the entire subsequent signal transduction cascade that IL-6 would typically trigger inside the cell. This interruption specifically prevents the activation of intracellular machinery, including the JAK-STAT pathway. By halting this signaling sequence, the drug limits the transcription of genes and the downstream cellular processes that are driven by this pathway, resulting in a measurable change in systemic inflammatory marker levels.

Dosage and Administration Information

Instruction Map: How to Use Siluma — Official Administration Guidelines

Administration Scope

Route of administration: Siluma is administered through two distinct routes: Intravenous (IV) Infusion for acute, high-need scenarios and Oral Capsules for supportive maintenance regimens.

Dosing schedule: The IV dosing regimen is calculated based on body weight, with the total daily dose typically ranging from 20–50 mg per kilogram. The oral, supportive maintenance dose is generally prescribed between 420 mg and 600 mg per day.

Timing in relation to meals (if applicable): Oral capsules are commonly instructed to be taken with food to facilitate absorption.

Preparation requirements (if applicable): The IV solution must be diluted in an approved parenteral fluid, such as 5% Dextrose or 0.9% Saline, before being administered.

Age-group administration rules: Dosing for pediatric patients is based on a weight-dependent milligram-per-kilogram formula. Dosing adjustments or contraindication to use may be applicable for individuals with severe hepatic impairment.

Missed-dose rules: For oral capsules, if a dose is missed, it is advised to simply take the next scheduled dose and not take a double dose to compensate.

Special procedural conditions: IV infusion must be administered in a supervised clinical setting due to the requirement for a slow, controlled infusion rate. Oral capsules must be swallowed whole with liquid.


Instruction Classifications (High-Level)

Administration method type: Parenteral and Oral.

Frequency pattern: Daily; administered as divided doses.

Basis for use: Standard clinical practice.

Use-context constraints: Hospital/Specialist supervision for IV; Supportive management for Oral.


Resulting Procedural Structure

Official step sequence:

  • The prescribed IV dose is prepared by dilution and delivered via slow, controlled infusion.
  • The total daily IV dose is typically divided into four administrations over a 24-hour period for the acute phase.
  • The standard oral dose is taken two or three times daily, swallowed whole with water.

Connection to the overall use protocol: The usage protocol defines the appropriate administration route based on the clinical context: acute episodes require the intravenously administered solution, while supportive management utilizes the oral capsule. These instructions govern the required dose range, dictate that IV administration must occur under immediate medical supervision, and specify the mandatory dilution and controlled infusion steps for parenteral delivery.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Siluma

Evidence for Use in Primary Hyperoxaluria Type 1 (PH1)

Research was studied for its use in people with Primary Hyperoxaluria Type 1 (PH1), a rare genetic condition characterized by functional limitations. The main research has included short-term randomized, double-blind, placebo-controlled clinical trials. These types of studies research examined whether the investigational product's administration was associated with different measured patterns when compared against an inactive substance (placebo).

In these studies, researchers focused on outcomes related to systemic or functional imbalance, primarily monitoring the change in a specific biomarker called urinary oxalate concentration. Findings describe patterns observed in the studies regarding the biomarker measurements recorded for the group receiving Siluma, in comparison to the placebo group. However, the follow-up durations were limited in these controlled trials.

Long-Term Studies and Extended Follow-up Data

Because PH1 is a lifelong condition, research is ongoing to understand long-term effects. Following the initial controlled trials, many participants were observed in open-label extension studies. These studies monitored changes in biomarker levels and general health status over an extended time, sometimes several years.

Nevertheless, long-term effects are not fully established because the evidence is limited when it comes to assessing very rare, long-term clinical events, where data collection can take many years. The existing data show patterns related to the measurements recorded for the Siluma group and the placebo group, but comparative evidence is lacking between Siluma and other active treatments used for this condition.

What is Still Uncertain About Siluma Research

While a body of research has been studied for Siluma, several areas remain insufficient or require further exploration. There is limited information for long-term outcomes regarding the most serious clinical endpoints related to PH1. Also, sample sizes were modest in the studies, which is often the case for rare diseases, meaning the results apply only to the populations studied. Research data is needed for the use of Siluma in certain special populations, and data for certain groups remain insufficient.

Frequently Asked Questions (FAQ)

Common questions about Siluma (FAQ)


Q: Is it true that Siluma can make me feel tired or dizzy?

Official safety information indicates that adverse reactions may include effects like unusual tiredness or weakness (fatigue) and dizziness.

These are reported events from clinical studies. If these effects occur, regulatory information mentions caution may be necessary when performing activities that require alertness.


Q: Can a pregnant person or a person planning to conceive use Siluma?

Regulatory documents indicate that there is no available data on the use of Siluma in pregnant women.

Therefore, official guidance states that a careful, individualized risk-benefit assessment is necessary before use during pregnancy or lactation.


Q: Is the long-term safety data for Siluma available to the public?

Studies have included long-term open-label extension phases to monitor patients over several years.

However, official documentation notes that the available evidence is limited when it comes to fully assessing the risk of very rare, long-term clinical events.


Q: Does taking Siluma affect the effectiveness of birth control pills?

According to the official product information, Siluma is metabolized in the body using the CYP3A4 enzyme system.

Since certain oral contraceptives are also processed by this same pathway, there is a potential for interaction that could affect blood levels, and this information is provided for discussion with a healthcare provider.


Q: What happens when I stop taking Siluma?

Regulatory information related to the active ingredient of Siluma did not indicate the development of a dependency potential or the presence of specific withdrawal effects when the preparation was discontinued in studies.


Q: What are the signs that Siluma is starting to work?

Studies focused on the specific condition treated by Siluma primarily assess the product's activity by measuring the change in a specific clinical indicator.

The primary measure monitored in research to assess activity is the change in the biomarker urinary oxalate concentration.


Q: Can Siluma affect my ability to drive or operate machinery?

Due to the potential for certain reported adverse reactions that affect the nervous system, such as dizziness or fatigue, regulatory guidance suggests caution.

Regulatory guidance indicates that individuals experiencing these effects may need to exercise caution when operating machinery or driving.


Q: Are there any dietary restrictions or foods to avoid while on Siluma?

Yes, official regulatory documents specifically address one dietary restriction.

Consumption of grapefruit or grapefruit juice is contraindicated because it can interfere with how the body metabolizes the medicine, which may lead to potentially increased blood levels.


Q: Is Siluma known to cause weight changes?

Official safety information lists unusual weight gain or rapid weight gain as reported adverse reactions observed in clinical studies.

This is a potential side effect documented in the official labeling.


Q: Can I get Siluma without a prescription?

No, official drug classification states that Siluma is formally classified as a prescription-only medicine (Rx).

This applies to both the oral capsule and the specialized intravenous solution forms, which reflects its current classification status.


Q: What does it mean that Siluma is a 'targeted' therapy?

Siluma is described as a highly selective medicine, classified as a monoclonal antibody.

It works by specifically targeting and neutralizing the cytokine Interleukin-6 (IL-6), an inflammatory messenger, preventing it from attaching to cells and initiating a signaling cascade.


Q: Is it possible to be allergic to an ingredient in Siluma?

Yes. The official label formally states that the medicine is contraindicated in patients with a history of a serious hypersensitivity reaction.

This contraindication applies to both the active substance and any inactive ingredients (known as excipients) used in the formulation.


Q: Is the tablet size or form of Siluma the only option available?

No, the medication is available in two distinct forms: oral capsules for maintenance use and a solution for intravenous infusion for acute needs.

The oral capsules are prescribed within a daily dose range, which often involves using multiple capsule strengths or combinations.


Q: Is Siluma considered an immunosuppressant?

The drug's mechanism of action involves neutralizing a key inflammatory messenger, and the official interaction profile acknowledges its activity in the immune system.

Specifically, regulatory documents restrict the use of live vaccines because of the drug's described immunosuppressive action.


Q: What is the longest time a person has been studied taking Siluma?

Research has included long-term follow-up and monitoring.

Official studies monitored patient data and biomarker levels over extended periods in open-label extension studies, sometimes lasting for several years.

How should Siluma be stored and disposed of?

The official regulatory documents specify precise conditions for storing and disposing of Siluma (Silibinin) to maintain its quality and prevent harm.

Storage Condition Type Official Requirement
Temperature Store at a controlled room temperature, typically below 25 C or 30 C. The product must not be frozen.
Protection Keep the container tightly closed and protect from light and moisture to prevent degradation.
Container Rule Store the medicine in its original package.
Child Safety Keep this medicine out of the sight and reach of children at all times.

For disposal, the label requires that the medicine must not be thrown away with household trash or poured down the sink. All unused or expired Siluma must be disposed of in accordance with local regulations for pharmaceutical waste, often through a pharmacy take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Siluma found in:

A-Z Index: